RTW Investments recently made a significant move by initiating a new stake in Apellis Pharmaceuticals (NASDAQ:APLS) during the fourth quarter. According to a SEC filing dated February 17, 2026, the investment firm acquired 7,666,764 shares of Apellis Pharmaceuticals, reflecting a stake valued at $192.59 million at the end of the quarter.
This marked a new position for RTW Investments, with Apellis accounting for 1.93% of its 13F reportable assets under management as of December 31, 2025. The firm’s top holdings post-filing included other biotech names like Madrigal, Insmed, and others, showcasing a strategic diversification within the healthcare sector.
Apellis Pharmaceuticals focuses on developing and commercializing therapeutic compounds that target the complement system. Key products in its portfolio include pegcetacoplan and EMPAVELI, which are used to treat autoimmune and inflammatory diseases. The company generates revenue through sales of its proprietary biopharmaceutical products and collaborative licensing agreements, catering to healthcare providers and patients in markets dealing with rare diseases such as geographic atrophy, paroxysmal nocturnal hemoglobinuria, and cold agglutinin disease.
As of the latest data, Apellis shares were priced at $17.21, down 29% over the past year, showing underperformance compared to the S&P 500. However, the company reported revenue of $1 billion in the trailing twelve months, with a net income of $22.4 million and a market capitalization of $2.2 billion. This indicates a solid financial foundation and potential for growth in the future.
The move by RTW Investments to invest in Apellis Pharmaceuticals signifies a calculated pivot towards more stable revenue streams while still retaining potential upside. With a growing commercial portfolio and strategic collaborations, Apellis is well-positioned to address significant unmet medical needs in the complement-driven diseases space.
In conclusion, the investment in Apellis Pharmaceuticals by RTW Investments reflects a strategic decision to diversify within the biotech sector and capitalize on the company’s growth potential in the rare disease and specialty therapeutics market. This move highlights the importance of disciplined investing in identifying opportunities with long-term growth prospects.
